Prothrombin complex concentrates as reversal agents for new oral anticoagulants: lessons from preclinical studies with Beriplex.
Although new oral anticoagulants (NOACs) represent an advance in anticoagulant therapy over vitamin K antagonists (VKAs), they nevertheless have a low, but significant risk for bleeding complications. Reversal agents for VKAs, such as prothrombin complex concentrates (PCCs), are currently being evaluated in preclinical studies for NOAC reversal. This article reviews the preclinical data for the most extensively studied PCC for NOAC reversal, Beriplex, a 4-factor PCC. The results from the Beriplex studies are also compared with those obtained with other reversal agents, including different nonactivated PCCs, activated PCCs, and recombinant activated factor VII.
['Dickneite|Gerhard|G|']
D000284:Administration, Oral D000818:Animals D000925:Anticoagulants D000991:Antithrombins D001777:Blood Coagulation D004305:Dose-Response Relationship, Drug D004338:Drug Combinations D004353:Drug Evaluation, Preclinical D005164:Factor IX D005167:Factor VII D005170:Factor X D065427:Factor Xa Inhibitors D006470:Hemorrhage D006487:Hemostasis D006490:Hemostatics D006801:Humans D008954:Models, Biological D011516:Prothrombin
Prothrombin complex concentrate New oral anticoagulants Beriplex Anticoagulant reversal